A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 1, 2016
End Date
July 15, 2020
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 1, 2016
End Date
July 15, 2020